{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002799","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.496819+00:00","generated_at":"2026-05-16T10:46:23.617507+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PTC Therapeutics: 2025 preliminary revenue ~$823M, Sephience $112M; 2026 guidance $700-800M product revenue","bullets":["Preliminary 2025 total product & royalty revenue ~$823.4M, exceeding prior guidance; product revenue ~$587.8M.","Sephience (sepiapterin) net revenue $112.1M since launch, Q4 alone $92.5M; 946 patients on commercial therapy as of Dec 31.","Closed sale of remaining Evrysdi royalty to Royalty Pharma for $240M upfront plus up to $60M milestones; retains $150M milestone.","2026 guidance: product revenue $700-800M (19-36% YoY growth); GAAP R&D/SG&A $775-815M, non-GAAP $680-720M.","End-of-Phase 2 meeting for votoplam HD program; Phase 3 trial to start H1 2026; FDA open to Accelerated Approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002799","json":"https://secwatch.observer/filing/0001104659-26-002799.json","markdown":"https://secwatch.observer/filing/0001104659-26-002799.md","text":"https://secwatch.observer/filing/0001104659-26-002799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000110465926002799/0001104659-26-002799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000110465926002799/tmb-20260112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:46:23.617507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}